





| 货号 | HX959076 |
|---|---|
| 品牌 | abinScience |
| 描述 |
Ispectamab (HX959076) is a research-grade recombinant antibody targeting CD269. Produced in mammalian cells with native-like glycosylation.
Highlights
|
| 种属反应性 | Human |
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| 宿主 | Human |
| 同种型 | IgG1-kappa |
| 表达系统 | Mammalian cells |
| 克隆类型 | Monoclonal |
| 经测试应用 | WB |
| 靶标 | Tumor necrosis factor receptor superfamily member 17, TNFRSF17, CD269, B-cell maturation protein, BCMA, BCM |
| 内毒素水平 | < 10 EU/mg |
| 纯度 | >95% purity as determined by SDS-PAGE. |
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
| Accession号 | Q02223 |
| 状态 | Liquid |
| 保存溶液 | 0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 别名 | BMS-986352, CC-99712, CC99712, CC99712, SP8919, 2413386-21-5 |
| 背景 | Tumor necrosis factor receptor superfamily member 17 (CD269/BCMA) is a ~20 kDa protein. Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. Promotes B-cell survival and plays a role in the regulation of humoral immunity. Activates NF-kappa-B and JNK. CD269 is the therapeutic target of teclistamab (Tecvayli). |
| Note | For research use only. Not suitable for clinical or therapeutic use. |

Western blot analysis was performed using anti-CD269 monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human CD269 (Catalog No: HX959012)
Lane 2: negative control

SDS-PAGE for Research Grade Ispectamab.

Detects recombinant human CD269/TNFRSF17/BCMA (Catalog No: HX959012) in indirect ELISA







24小时产品查询

扫一扫关注我们

专属渠道经理